BCG Vaccine Market Research, 2030

The global BCG vaccine market size was valued at $46,637.5 thousands in 2020, and is projected to reach $74,269.55 thousands by 2030, registering a CAGR of 4.8% from 2021 to 2030. Bacillus Calmette-Gurin (BCG) vaccine is the only vaccine currently available for prevention of tuberculosis (TB). In countries with high prevalence of tuberculosis, one dose is recommended for healthy babies. However, in areas where tuberculosis is uncommon, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested and treated. Adults not infected with tuberculosis and who have not been previously immunized but are frequently exposed to drug-resistant tuberculosis may be immunized as well. However, side effects associated with the BCG vaccine such as headache, head glands swollen, high temperature, and soreness at the site of injection is predicted to limit the use of BCG vaccines among certain individuals.  

Get more information on this report : Request Sample Pages

The factors that drive the global BCG vaccine market include increase in prevalence of tuberculosis, especially in developing and underdeveloped countries, and technological advancement in the field of vaccine research. Moreover, rise in demand for BCG vaccines due to surge in number of newborn babies across the globe, increase in government initiatives, and rise in focus on immunization programs globally further boost the market growth. However, side effects of the BCG vaccine and a global shortage of this vaccine restrict the market growth. Untapped market opportunities in developing regions are expected to provide numerous prospects for market development.

COVID-19 Scenario Analysis

Coronavirus (COVID-19) was discovered in late December, 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. The outbreak of COVID-19 pandemic has not affected the BCG vaccine market as BCG vaccination among pediatric population has not decreased. Moreover, BCG vaccination decreases susceptibility to respiratory tract infections and improves immunity in pediatrics. Moreover, few countries did some clinical trials on humans to see the effectiveness of BCG vaccine towards COVID-19, which boosts the market growth. Thus, the COVID-19 pandemic has a positive impact on the BCG vaccine market.

The BCG vaccine market is segmented on the basis of demographics, and region. On the basis of demographics, it is bifurcated into pediatrics (0-18 Years) and adults (19-35 years). Region wise, the market is analyzed across Asia-Pacific, LAMEA, and Rest of the World.

Demographics Segment Review

The pediatrics (0-18 Years) segment held a major share of the BCG vaccine market in 2020, and is expected to maintain its dominance during the forecast period. BCG is generally administered to all infants up to one year of age in countries where BCG vaccination is a part of the national childhood immunization program. In addition, this vaccine can also be given to older children (more than 1 year of age) who have increased risk of developing tuberculosis. It is rarely given above the age of 16, and rarely administered above the age of 35 as vaccinations are effective only when administered in early stages of life. Thus, aforementioned factor drives the growth of pediatrics (0-18 Years) segment during the forecast period.

Region Segment Review

Rest of the World accounted for major share of the global BCG vaccine market in 2020, and is expected to remain dominant during the forecast period. This was attributed to increase in prevalence of tuberculosis, rise in number of immunization programs, availability of advanced healthcare facilities with trained medical professionals, presence of most of the key players, and surge in investment made by governments in the healthcare system. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period, majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, development of the R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare.

[DEMOGRAPHICSGRAPH]

Moreover, BCG vaccination is part of the immunization schedule of the Kenya Expanded Program on Immunization (KEPI). Therefore, the vaccine is administered to all children born in Kenyan hospitals. The vaccine is administered as an injection (single dose) on the left forearm of infants immediately after birth. Moreover, in this region, BCG vaccine is generally given along with polio and Hepatitis B vaccines to infants after birth.

The list of key players profiled in this report include AJ Biologics, China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation), Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), Statens Serum Institut, and Torlak Institute of Virology.

[REGIONGRAPH]

Key Benefits for Stakeholders

• This report provides a detailed quantitative analysis of the current BCG vaccine Market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
• An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
• A comprehensive analysis of factors that drive and restrain the growth of the global the BCG vaccine market is provided.
• The projections in this report are made by analyzing the current trends and future market potential from 2020 to 2030, in terms of value.
• An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
• Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help in understanding competitive outlook of the market.

 Key Market Segments

• By Demographics
  • Pediatrics (0-18 Years)
  • Adults (19-35 years)
• By Region
  • Asia Pacific
    • India
    • China
    • Bangladesh
    • Pakistan
    • Indonesia
    • Japan
    • Thailand
    • Singapore
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Mexico
    • South Africa
    • Kenya
    • Argentina
    • Colombia
    • Chile
    • Rest of LAMEA
  • REST OF THE WORLD
• By Key Market Players
  • AJ Biologics
  • China National group corporation (Sinopharm)
  • Greensignal Biopharma Limited
  • Intervax Ltd.
  • Japan BCG Laboratory
  • Merck & Co., Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Stetens Serum Institute
  • Torlak Institute of Virology

CHAPTER 1:  INTRODUCTION

1.1.Report Description
1.2.Key Market Segments
1.3.Key Benefits
1.4.Research Methodology

1.4.1.Primary Research
1.4.2.Secondary Research
1.4.3.Analyst Tools and Models

CHAPTER 2:  EXECUTIVE SUMMARY

2.1.CXO Perspective

CHAPTER 3:  MARKET LANDSCAPE

3.1.Market Definition and Scope
3.2.Key Findings

3.2.1.Top Investment Pockets
3.2.2.Top Winning Strategies

3.3.Porter's Five Forces Analysis

3.3.1.Bargaining Power of Suppliers
3.3.2.Threat of New Entrants
3.3.3.Threat of Substitutes
3.3.4.Competitive Rivalry
3.3.5.Bargaining Power among Buyers

3.4.Market Share Analysis/Top Player Positioning

3.4.1.Market Share Analysis/Top Player Positioning 2020

3.5.Market Dynamics

3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities

3.6.  COVID-19 Impact Analysis

CHAPTER 4:  BCG VACCINE MARKET, BY DEMOGRAPHICS

4.1.Market Overview

 4.1.1Market Size and Forecast, By Demographics

4.2.PEDIATRICS (AGE 0-18 YEARS)

4.2.1.Key Market Trends, Growth Factors and Opportunities
4.2.2.Market Size and Forecast, By Region 
4.2.3.Market Share Analysis, By Country

4.3.ADULTS (AGE 19-35 YEARS)

4.3.1.Key Market Trends, Growth Factors and Opportunities
4.3.2.Market Size and Forecast, By Region 
4.3.3.Market Share Analysis, By Country

CHAPTER 5:  BCG VACCINE MARKET, BY REGION

5.1.Market Overview

 5.1.1Market Size and Forecast, By Region

5.2.Asia-Pacific

5.2.1.Key Market Trends and Opportunities
5.2.2.Market Size and Forecast, By Demographics
5.2.3.Market Size and Forecast, By Country
5.2.4.India BCG Vaccine Market

5.2.4.1.Market Size and Forecast, By Demographics

5.2.5.China BCG Vaccine Market

5.2.5.1.Market Size and Forecast, By Demographics

5.2.6.Bangladesh BCG Vaccine Market

5.2.6.1.Market Size and Forecast, By Demographics

5.2.7.Pakistan BCG Vaccine Market

5.2.7.1.Market Size and Forecast, By Demographics

5.2.8.Indonesia BCG Vaccine Market

5.2.8.1.Market Size and Forecast, By Demographics

5.2.9.Japan BCG Vaccine Market

5.2.9.1.Market Size and Forecast, By Demographics

5.2.10.Thailand BCG Vaccine Market

5.2.10.1.Market Size and Forecast, By Demographics

5.2.11.Singapore BCG Vaccine Market

5.2.11.1.Market Size and Forecast, By Demographics

5.2.12.Rest Of Asia-pacific BCG Vaccine Market

5.2.12.1.Market Size and Forecast, By Demographics

5.3.LAMEA

5.3.1.Key Market Trends and Opportunities
5.3.2.Market Size and Forecast, By Demographics
5.3.3.Market Size and Forecast, By Country
5.3.4.Brazil BCG Vaccine Market

5.3.4.1.Market Size and Forecast, By Demographics

5.3.5.Mexico BCG Vaccine Market

5.3.5.1.Market Size and Forecast, By Demographics

5.3.6.South Africa BCG Vaccine Market

5.3.6.1.Market Size and Forecast, By Demographics

5.3.7.Kenya BCG Vaccine Market

5.3.7.1.Market Size and Forecast, By Demographics

5.3.8.Argentina BCG Vaccine Market

5.3.8.1.Market Size and Forecast, By Demographics

5.3.9.Colombia BCG Vaccine Market

5.3.9.1.Market Size and Forecast, By Demographics

5.3.10.Chile BCG Vaccine Market

5.3.10.1.Market Size and Forecast, By Demographics

5.3.11.Rest of LAMEA BCG Vaccine Market

5.3.11.1.Market Size and Forecast, By Demographics

5.4.Rest of the World

5.4.1.Key Market Trends and Opportunities
5.4.2.Market Size and Forecast, By Demographics

CHAPTER 6:  COMPANY PROFILES

6.1.AJ Biologics

6.1.1.Company Overview
6.1.2.Key Executives
6.1.3.Company snapshot
6.1.4.Operating business segments
6.1.5.Product portfolio
6.1.6.Business Performance
6.1.7.Key Strategic Moves and Developments

6.2.China National Group Corporation (Sinopharm)

6.2.1.Company Overview
6.2.2.Key Executives
6.2.3.Company snapshot
6.2.4.Operating business segments
6.2.5.Product portfolio
6.2.6.Business Performance
6.2.7.Key Strategic Moves and Developments

6.3.Greensignal Biopharma Limited

6.3.1.Company Overview
6.3.2.Key Executives
6.3.3.Company snapshot
6.3.4.Operating business segments
6.3.5.Product portfolio
6.3.6.Business Performance
6.3.7.Key Strategic Moves and Developments

6.4.Intervax Ltd.

6.4.1.Company Overview
6.4.2.Key Executives
6.4.3.Company snapshot
6.4.4.Operating business segments
6.4.5.Product portfolio
6.4.6.Business Performance
6.4.7.Key Strategic Moves and Developments

6.5.Japan BCG Laboratory

6.5.1.Company Overview
6.5.2.Key Executives
6.5.3.Company snapshot
6.5.4.Operating business segments
6.5.5.Product portfolio
6.5.6.Business Performance
6.5.7.Key Strategic Moves and Developments

6.6.Merck And Co., Inc.

6.6.1.Company Overview
6.6.2.Key Executives
6.6.3.Company snapshot
6.6.4.Operating business segments
6.6.5.Product portfolio
6.6.6.Business Performance
6.6.7.Key Strategic Moves and Developments

6.7.Sanofi

6.7.1.Company Overview
6.7.2.Key Executives
6.7.3.Company snapshot
6.7.4.Operating business segments
6.7.5.Product portfolio
6.7.6.Business Performance
6.7.7.Key Strategic Moves and Developments

6.8.Serum Institute Of India Pvt. Ltd.

6.8.1.Company Overview
6.8.2.Key Executives
6.8.3.Company snapshot
6.8.4.Operating business segments
6.8.5.Product portfolio
6.8.6.Business Performance
6.8.7.Key Strategic Moves and Developments

6.9.Stetens Serum Institute

6.9.1.Company Overview
6.9.2.Key Executives
6.9.3.Company snapshot
6.9.4.Operating business segments
6.9.5.Product portfolio
6.9.6.Business Performance
6.9.7.Key Strategic Moves and Developments

6.10.Torlak Institute Of Virology

6.10.1.Company Overview
6.10.2.Key Executives
6.10.3.Company snapshot
6.10.4.Operating business segments
6.10.5.Product portfolio
6.10.6.Business Performance
6.10.7.Key Strategic Moves and Developments

LIST OF TABLES

TABLE 1.GLOBAL BCG VACCINE MARKET, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 2.GLOBAL BCG VACCINE MARKET FOR PEDIATRICS (AGE 0-18 YEARS), BY REGION, 2020-2030 ($MILLION)
TABLE 3.GLOBAL BCG VACCINE MARKET FOR ADULTS (AGE 19-35 YEARS), BY REGION, 2020-2030 ($MILLION)
TABLE 4.GLOBAL BCG VACCINE MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 5.ASIA-PACIFIC BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 6.INDIA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 7.CHINA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 8.BANGLADESH BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 9.PAKISTAN BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 10.INDONESIA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 11.JAPAN BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 12.THAILAND BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 13.SINGAPORE BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 14.REST OF ASIA-PACIFIC BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 15.LAMEA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 16.BRAZIL BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 17.MEXICO BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 18.SOUTH AFRICA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 19.KENYA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 20.ARGENTINA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 21.COLOMBIA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 22.CHILE BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 23.REST OF LAMEA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 24.REST OF THE WORLD BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
TABLE 25.AJ BIOLOGICS: KEY EXECUTIVES
TABLE 26.AJ BIOLOGICS: COMPANY SNAPSHOT
TABLE 27.AJ BIOLOGICS: OPERATING SEGMENTS
TABLE 28.AJ BIOLOGICS: PRODUCT PORTFOLIO
TABLE 29.AJ BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 30.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): KEY EXECUTIVES
TABLE 31.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): COMPANY SNAPSHOT
TABLE 32.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): OPERATING SEGMENTS
TABLE 33.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): PRODUCT PORTFOLIO
TABLE 34.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 35.GREENSIGNAL BIOPHARMA LIMITED: KEY EXECUTIVES
TABLE 36.GREENSIGNAL BIOPHARMA LIMITED: COMPANY SNAPSHOT
TABLE 37.GREENSIGNAL BIOPHARMA LIMITED: OPERATING SEGMENTS
TABLE 38.GREENSIGNAL BIOPHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 39.GREENSIGNAL BIOPHARMA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 40.INTERVAX LTD.: KEY EXECUTIVES
TABLE 41.INTERVAX LTD.: COMPANY SNAPSHOT
TABLE 42.INTERVAX LTD.: OPERATING SEGMENTS
TABLE 43.INTERVAX LTD.: PRODUCT PORTFOLIO
TABLE 44.INTERVAX LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 45.JAPAN BCG LABORATORY: KEY EXECUTIVES
TABLE 46.JAPAN BCG LABORATORY: COMPANY SNAPSHOT
TABLE 47.JAPAN BCG LABORATORY: OPERATING SEGMENTS
TABLE 48.JAPAN BCG LABORATORY: PRODUCT PORTFOLIO
TABLE 49.JAPAN BCG LABORATORY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 50.MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 51.MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 52.MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 53.MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 54.MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 55.SANOFI: KEY EXECUTIVES
TABLE 56.SANOFI: COMPANY SNAPSHOT
TABLE 57.SANOFI: OPERATING SEGMENTS
TABLE 58.SANOFI: PRODUCT PORTFOLIO
TABLE 59.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 60.SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
TABLE 61.SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 62.SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS
TABLE 63.SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 64.SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 65.STETENS SERUM INSTITUTE: KEY EXECUTIVES
TABLE 66.STETENS SERUM INSTITUTE: COMPANY SNAPSHOT
TABLE 67.STETENS SERUM INSTITUTE: OPERATING SEGMENTS
TABLE 68.STETENS SERUM INSTITUTE: PRODUCT PORTFOLIO
TABLE 69.STETENS SERUM INSTITUTE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 70.TORLAK INSTITUTE OF VIROLOGY: KEY EXECUTIVES
TABLE 71.TORLAK INSTITUTE OF VIROLOGY: COMPANY SNAPSHOT
TABLE 72.TORLAK INSTITUTE OF VIROLOGY: OPERATING SEGMENTS
TABLE 73.TORLAK INSTITUTE OF VIROLOGY: PRODUCT PORTFOLIO
TABLE 74.TORLAK INSTITUTE OF VIROLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
 
LIST OF FIGURES

FIGURE 1.GLOBAL BCG VACCINE MARKET SEGMENTATION
FIGURE 2.GLOBAL BCG VACCINE MARKET
FIGURE 3.SEGMENTATION BCG VACCINE MARKET
FIGURE 4.TOP INVESTMENT POCKET IN BCG VACCINE MARKET
FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.LOW THREAT OF SUBSTITUTION
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.TOP PLAYER POSITIONING, 2020
FIGURE 14.MARKET SHARE ANALYSIS, 2020
FIGURE 15.RESTRAINTS AND DRIVERS: BCG VACCINE MARKET
FIGURE 16.BCG VACCINE MARKET SEGMENTATION, BY DEMOGRAPHICS
FIGURE 17.BCG VACCINE MARKET FOR PEDIATRICS (AGE 0-18 YEARS), BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.BCG VACCINE MARKET FOR ADULTS (AGE 19-35 YEARS), BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 19.AJ BIOLOGICS: NET SALES, 2018-2020 ($MILLION)
FIGURE 20.AJ BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 21.AJ BIOLOGICS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 22.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): NET SALES, 2018-2020 ($MILLION)
FIGURE 23.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 24.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 25.GREENSIGNAL BIOPHARMA LIMITED: NET SALES, 2018-2020 ($MILLION)
FIGURE 26.GREENSIGNAL BIOPHARMA LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 27.GREENSIGNAL BIOPHARMA LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 28.INTERVAX LTD.: NET SALES, 2018-2020 ($MILLION)
FIGURE 29.INTERVAX LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 30.INTERVAX LTD.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 31.JAPAN BCG LABORATORY: NET SALES, 2018-2020 ($MILLION)
FIGURE 32.JAPAN BCG LABORATORY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 33.JAPAN BCG LABORATORY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 34.MERCK AND CO., INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 35.MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 36.MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 37.SANOFI: NET SALES, 2018-2020 ($MILLION)
FIGURE 38.SANOFI: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.SANOFI: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES, 2018-2020 ($MILLION)
FIGURE 41.SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 43.STETENS SERUM INSTITUTE: NET SALES, 2018-2020 ($MILLION)
FIGURE 44.STETENS SERUM INSTITUTE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 45.STETENS SERUM INSTITUTE: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 46.TORLAK INSTITUTE OF VIROLOGY: NET SALES, 2018-2020 ($MILLION)
FIGURE 47.TORLAK INSTITUTE OF VIROLOGY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 48.TORLAK INSTITUTE OF VIROLOGY: REVENUE SHARE, BY REGION, 2020 (%)